[en] Rheumatic Heart Disease (RHD) is well known to be an active inflammatory process which develops progressive calcification and leaflet thickening over time. The potential for statin therapy in slowing the progression of valvular heart disease is still controversial. Retrospective studies have shown that medical therapy is beneficial for patients with calcific aortic stenosis and recently for rheumatic valve disease. However, the prospective randomized clinical trials have been negative to date. This article discusses the epidemiologic risk factors, basic science, retrospective and prospective studies in valvular heart disease and a future clinical trial to target RHD with statin therapy to slow the progression of this disease. Recent epidemiological studies have revealed the risk factors associated with valvular disease include male gender, smoking, hypertension and elevated serum cholesterol and are similar to the risk factors for vascular atherosclerosis. An increasing number of models of experimental hypercholesterolemia demonstrate features of atherosclerosis in the aortic valve (AV), which are similar to the early stages of vascular atherosclerotic lesions. Calcification, the end stage process of the disease, must be understood as a prognostic indicator in the modification of this cellular process before it is too late. This is important in calcific aortic stenosis as well as in rheumatic valve disease. There are a growing number of studies that describe similar pathophysiologic molecular markers in the development of rheumatic valve disease as in calcific aortic stenosis. In summary, these findings suggest that medical therapies may have a potential role in patients in the early stages of this disease process to slow the progression of RHD affecting the valves. This review will summarize the potential for statin therapy for this patient population.
Carapetis JR, McDonald M, Wilson NJ. Acute rheumatic fever. Lancet 2005;366:155-168 (Pubitemid 40991218)
Rheumatic fever and rheumatic heart disease: Report of WHO Expert Consultation. October-1 November 2001. World Health Organization Geneva,;Geneva, 2004.
Essop MR, Nkomo VT. Rheumatic and nonrheumatic valvular heart disease: epidemiology, management, and prevention in Africa. Circulation 2005;112:3584-3591 (Pubitemid 43739536)
Carapetis JR. Rheumatic heart disease in Asia. Circulation 2008;118:2748-2753
Lancisi GM. De subitaneis mortibus libri duo. Leipzig 1709.
Seiegel A, Johnson E, Stollerman G. Controlled studies of streptococcalpharyngitis in a pediatric population,1: factors related to teh attach rate of rheumatic fever. N Engl Med 1961;265:559-565.
Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of Rheumatic Fever and Diagnosis and Treatment of Acute Streptococcal Pharyngitis. A Scientific Statement From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research. Circulation 2009.
Bonow RO, Carabello BA, Kanu C, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 2006;114:e84-231. (Pubitemid 44268973)
Wilkins GT, Weyman AE, Abascal VM,et al. Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation. Br Heart J 1988;60:299-308.
Deutscher S, Rockette HE, Krishnaswami V. Diabetes and hypercholesterolemia among patients with calcific aortic stenosis. J Chronic Dis 1984;37:407-415 (Pubitemid 14134891)
Hoagland PM, Cook EF, Flatley M,et al. Case-control analysis of risk factors for presence of aortic stenosis in adults (age 50 years or older). Am J Cardiol 1985;55:744-747 (Pubitemid 15148253)
Aronow WS, Ahn C, Kronzon I, Goldman ME. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. American Journal of Cardiology 2001;88:693-695 (Pubitemid 32831111)
Aronow WS, Schwartz KS, Koenigsberg M. Correlation of serum lipids, calcium, and phosphorus, diabetes mellitus and history of systemic hypertension with presence or absence of calcified or thickened aortic cusps or root in elderly patients. Am J Cardiol 1987;59:998-999 (Pubitemid 17074253)
Mohler ER, Sheridan MJ, Nichols R,et al. Development and progression of aortic valve stenosis: atherosclerosis risk factors - a causal relationship? A clinical morphologic study. Clin Cardiol 1991;14:995-999
Lindroos M, Kupari M, Valvanne J,et al. Factors associated with calcific aortic valve degeneration in the elderly. Eur Heart J 1994;15:865-870
Boon A, Cheriex E, Lodder J, Kessels F. Cardiac valve calcification: characteristics of patients with calcification of the mitral annulus or aortic valve. Heart 1997;78:472-474 (Pubitemid 27515107)
Chui MC, Newby DE, Panarelli M, et al. Association between calcific aortic stenosis and hypercholesterolemia: is there a need for a randomized controlled trial of cholesterol-lowering therapy? Clin Cardiol 2001;24:52-55
Wilmshurst PT, Stevenson RN, Griffiths H, Lord JR. A case-control investigation of the relation between hyperlipidaemia and calcific aortic valve stenosis. Heart 1997;78:475-479 (Pubitemid 27515108)
Chan KL, Ghani M, Woodend K, Burwash IG. Case-controlled study to assess risk factors for aortic stenosis in congenitally bicuspid aortic valve. Am J Cardiol 2001;88:690-693 (Pubitemid 32831110)
Briand M, Lemieux I, Dumesnil JG, et al. Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. J Am Coll Cardiol 2006;47:2229-2236 (Pubitemid 43795081)
Palta S, Pai AM, Gill KS, Pai RG. New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation 2000;101:2497-2502 (Pubitemid 30366254)
Peltier M, Trojette F, Sarano ME, et al. Relation between cardiovascular risk factors and nonrheumatic severe calcific aortic stenosis among patients with a three-cuspid aortic valve. Am J Cardiol 2003;91:97-99 (Pubitemid 36050783)
Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. Journal of the American College of Cardiology 1997;29:630-634
Otto CM, Lind BK, Kitzman DW, et al. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly.[comment]. New England Journal of Medicine 1999;341:142-147 (Pubitemid 29325741)
Faggiano P, Antonini-Canterin F, Baldessin F, et al. Epidemiology and cardiovascular risk factors of aortic stenosis. Cardiovasc Ultrasound 2006;4:27. (Pubitemid 44252069)
Pohle K, Maffert R, Ropers D, et al. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation 2001;104:1927-1932 (Pubitemid 32983236)
Aronow WS, Ahn C, Kronzon I. Association of mitral annular calcium with symptomatic peripheral arterial disease in older persons. Am J Cardiol 2001;88:333-334 (Pubitemid 32721972)
Yilmaz MB, Demirkan B, Caldir V, et al. Association of lipid profile with echocardiographic Wilkins score in patients with moderate to severe mitral stenosis: possible impact on prognosis. Int J Cardiol 2006;112:329-333 (Pubitemid 44415047)
Rosenhek R, Binder T, Porenta G, et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 2000;343:611-617 (Pubitemid 30659472)
Coombs C. Rheumatic Heart Disease. Bristol: John Wright and Sons LTD. 1924:5-13.
Edwards WD, Peterson K, Edwards JE. Active valvulitis associated with chronic rheumatic valvular disease and active myocarditis. Circulation 1978;57:181-185 (Pubitemid 8254696)
Rajamannan NM, Subramaniam M, Rickard D, et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 2003;107:2181-2184 (Pubitemid 36547209)
Mohler ER, 3rd, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS. Bone formation and inflammation in cardiac valves. Circulation 2001;103:1522-1528
Rajamannan NM, Nealis TB, Subramaniam M, et al. Calcified rheumatic valve neoangiogenesis is associated with vascular endothelial growth factor expression and osteoblast-like bone formation. Circulation 2005;111:3296-3301 (Pubitemid 40875003)
Rajamannan NM, Subramaniam M, Springett M, et al. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation 2002;105:2260-2265 (Pubitemid 34596044)
Rajamannan NM, Sangiorgi G, Springett M, et al. Experimental hypercholesterolemia induces apoptosis in the aortic valve. Journal of Heart Valve Disease 2001;10:371-374 (Pubitemid 32454760)
Drolet MC, Arsenault M, Couet J. Experimental aortic valve stenosis in rabbits. Journal of the American College of Cardiology 2003;41:1211-1217 (Pubitemid 36384911)
Weiss RM, Ohashi M, Miller JD, Young SG, Heistad DD. Calcific aortic valve stenosis in old hypercholesterolemic mice. Circulation 2006;114:2065-2069 (Pubitemid 44706883)
Aikawa E, Nahrendorf M, Sosnovik D, et al. Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation 2007;115:377-386 (Pubitemid 46148512)
Drolet MC, Roussel E, Deshaies Y, et al. A high fat/high carbohydrate diet induces aortic valve disease in C57BL/6J mice. J Am Coll Cardiol 2006;47:850-855 (Pubitemid 43243111)
Shuvy M, Abedat S, Beeri R, et al. Uraemic hyperparathyroidism causes a reversible inflammatory process of aortic valve calcification in rats. Cardiovasc Res 2008;79:492-499
Antonini-Canterin F, Hirsu M, Popescu BA, et al. Stage-related effect of statin treatment on the progression of aortic valve sclerosis and stenosis. Am J Cardiol 2008;102:738-742
Sarphie TG. Interactions of IgG and beta-VLDL with aortic valve endothelium from hypercholesterolemic rabbits.1987 Dec.199-212 . (Pubitemid 17159772)
Sarphie TG. A cytochemical study of the surface properties of aortic and mitral valve endothelium from hypercholesterolemic rabbits.1986 Jun,281-296 . (Pubitemid 16012122)
Sarphie TG. Anionic surface properties of aortic and mitral valve endothelium from New Zealand white rabbits.1985 Oct.145-160 (Pubitemid 15248459)
Sarphie TG. Surface responses of aortic valve endothelia from diet-induced, hypercholesterolemic rabbits. 1985 Mar.283-299 (Pubitemid 15135416)
Cimini M, Boughner DR, Ronald JA,et al. Development of aortic valve sclerosis in a rabbit model of atherosclerosis: an immunohistochemical and histological study. J Heart Valve Dis 2005;14:365-375 (Pubitemid 47050751)
Rajamannan N M, Subramaniam M, Caira F, et al. Atorvastatin inhibits hypercholesterolemiainduced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation 2005;112:I229- 34.
Miller JD, Chu Y, Brooks RM,et al. Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. J Am Coll Cardiol 2008;52:843-850
Osman L, Yacoub MH, Latif N, et al. Role of human valve interstitial cells in valve calcification and their response to atorvastatin. Circulation 2006;114:I547-52. (Pubitemid 44297206)
Osman L, Chester AH, Amrani M,et al. A novel role of extracellular nucleotides in valve calcification: a potential target for atorvastatin. Circulation 2006;114:I566-72.
Arishiro K, Hoshiga M, Negoro N, et al. Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits. J Am Coll Cardiol 2007;49:1482-1489 (Pubitemid 46482919)
Rajamannan NM, Subramaniam M, Stock SR, et al. Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart 2005;91:806-810 (Pubitemid 40769233)
Makkena B, Salti H, Subramaniam M, et al. Atorvastatin decreases cellular proliferation and bone matrix expression in the hypercholesterolemic mitral valve. J Am Coll Cardiol 2005;45:631-633 (Pubitemid 40222262)
Osman L, Amrani M, Isley C,et al. Stimulatory effects of atorvastatin on extracellular nucleotide degradation in human endothelial cells. Nucleosides Nucleotides Nucleic Acids 2006;25:1125-1128
Rosenhek R, Binder T, Porenta G, et al. Predictors of outcome in severe asymptomatic aortic stenosis. NEJM 2000;343:611-617 (Pubitemid 30659472)
Otto CM, Burwash IG, Legget ME, et al. Prospective Study of Asymptomatic Valvular Aortic Stenosis : Clinical, Echocardiographic, and Exercise Predictors of Outcome. Circulation 1997;95:2262-2270.
Rosenhek R, Klaar U, Schemper M, et al. Mild and moderate aortic stenosis. Natural history and risk stratification by echocardiography. Eur Heart J 2004;25:199-205.
Herrmann HC, Wilkins GT, Abascal VM, et al. Percutaneous balloon mitral valvotomy for patients with mitral stenosis. Analysis of factors influencing early results. J Thorac Cardiovasc Surg 1988;96:33-38 (Pubitemid 18172840)
Bellamy MF, Pellikka PA, Klarich KW,et al.Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community.[comment]. Journal of the American College of Cardiology 2002;40:1723-1730 (Pubitemid 35341948)
Novaro GM, Tiong IY, Pearce GL,et al. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation 2001;104:2205-2209
Rosenhek R, Rader F, Loho N, et al. Statins but not angiotensin- converting enzyme inhibitors delay progression of aortic stenosis. Circulation 2004;110:1291-1295 (Pubitemid 39202347)
Shavelle DM, Takasu J, Budoff MJ,et al. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 2002;359:1125-1126
O'Brien KD, Probstfield JL, Caulfield MT, et al. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch Intern Med 2005;165:858-862 (Pubitemid 40563231)
Antonini-Canterin F, Leiballi E, Enache R, et al. Hydroxymethylglutaryl coenzyme-A reductase inhibitors delay the progression of rheumatic aortic valve stenosis. A long-term echocardiographic study. J Am Coll Cardiol 2009;In press.
Golbasi Z, Ucar O, Keles T, et al. Increased levels of high sensitive C-reactive protein in patients with chronic rheumatic valve disease: evidence of ongoing inflammation. Eur J Heart Fail 2002;4:593-595 (Pubitemid 35278511)
Galante A, Pietroiusti A, Vellini M, et al. C-reactive protein is increased in patients with degenerative aortic valvular stenosis. J Am Coll Cardiol 2001;38:1078-1082 (Pubitemid 32912714)
Skoutelis A, Freinkel RK, Kaufman DS, Leibovich SJ. Angiogenic activity is defective in monocytes from patients with alopecia universalis. J Invest Dermatol 1990;95:139-143 (Pubitemid 20254998)
Antonini-Canterin F, Zuppiroli A, Popescu BA, et al. Effect of statins on the progression of bioprosthetic aortic valve degeneration.1479-82, 2003 Dec 15.
Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005;352:2389-2397 (Pubitemid 40958435)
Rossebo AB, Pedersen TR, Boman K, et al. Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis. N Engl J Med 2008.
Moura LM, Ramos SF, Zamorano JL, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 2007;49:554-561 (Pubitemid 46177435)
Otto CM. Doppler Echocardiographic Evaluation of Aortic and Mitral Stenoses. Echocardiography 1999;16:675-676. (Pubitemid 29483235)
Agmon Y, Khandheria BK, Jamil Tajik A, et al. Inflammation, infection, and aortic valve sclerosis; Insights from the Olmsted County (Minnesota) population. Atherosclerosis 2004;174:337-342
Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. Jama 2001;286:64-70. (Pubitemid 32606333)
